 I'm Victoria Lang with your traffic report. Deal valued at roughly $3.2 billion. Lilly says the acquisition would improve outcomes for patients with inflammatory bowel disease. Morphic stock jumped more than 76% in pre-market trading. Morphic finished today up 75%, while shares of Lilly grew 0.3%.